Cellanome vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cellanome is building a multi-omics platform combining genome sequencing, microfluidics, and integrated sensors to measure biological data at single-cell resolution; raised $100M Series A in 2023;
About
Cellanome is a biotechnology tools company founded in 2021 and headquartered in Menlo Park, California. The company is developing a next-generation multi-omics platform designed to simultaneously measure multiple layers of biological information — including genomics, transcriptomics, and proteomics — at single-cell resolution and at unprecedented scale. Its platform integrates genome sequencing, microfluidics, and proprietary integrated sensors to capture a more complete molecular portrait of individual cells than any existing single-omics technology can achieve alone.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.